0.9296
-0.0504
(-5.14%)
At close: January 13 at 4:00:01 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 2 | 5 | 5 |
| Avg. Estimate | -0.1 | -0.09 | -0.47 | -0.44 |
| Low Estimate | -0.13 | -0.13 | -0.5 | -0.53 |
| High Estimate | -0.04 | -0.04 | -0.42 | -0.36 |
| Year Ago EPS | -0.08 | -0.17 | -0.53 | -0.47 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 2 | 7 | 7 |
| Avg. Estimate | 294.43k | 100k | 1.68M | 2.98M |
| Low Estimate | -- | -- | 1.4M | -- |
| High Estimate | 1M | 200k | 2.4M | 16.14M |
| Year Ago Sales | 6.34M | 230k | 8.23M | 1.68M |
| Sales Growth (year/est) | -95.36% | -56.52% | -79.62% | 78.04% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.07 | -0.14 | -0.14 | -0.12 |
| EPS Actual | -0.08 | -0.17 | -0.1 | -0.1 |
| Difference | -0.01 | -0.03 | 0.04 | 0.02 |
| Surprise % | -14.29% | -19.30% | 25.93% | 19.54% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.1 | -0.09 | -0.47 | -0.44 |
| 7 Days Ago | -0.11 | -0.11 | -0.48 | -0.48 |
| 30 Days Ago | -0.11 | -0.11 | -0.49 | -0.5 |
| 60 Days Ago | -0.11 | -0.11 | -0.5 | -0.52 |
| 90 Days Ago | -0.11 | -0.11 | -0.49 | -0.5 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 4 | 1 | 4 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CLSD | -22.50% | 50.00% | 11.32% | 6.81% |
| S&P 500 | 8.58% | 11.41% | 13.97% | 13.43% |
Upgrades & Downgrades
| Maintains | Chardan Capital: Buy to Buy | 11/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2024 |
| Reiterates | Needham: Buy to Buy | 11/13/2024 |
| Maintains | Chardan Capital: Buy to Buy | 10/14/2024 |
| Maintains | Needham: Buy to Buy | 10/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/27/2024 |
Related Tickers
ACET Adicet Bio, Inc.
0.8746
-4.63%
LPTX Leap Therapeutics, Inc.
3.1000
+1.31%
KPTI Karyopharm Therapeutics Inc.
0.6728
-6.37%
EYPT EyePoint Pharmaceuticals, Inc.
7.75
-7.07%
ATNM Actinium Pharmaceuticals, Inc.
1.2600
-1.56%
STRO Sutro Biopharma, Inc.
1.7900
-3.24%
CRVS Corvus Pharmaceuticals, Inc.
5.20
-2.44%
XLO Xilio Therapeutics, Inc.
1.1000
0.00%
RGNX REGENXBIO Inc.
6.95
-7.46%
CTMX CytomX Therapeutics, Inc.
0.8874
+0.83%